These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34850863)

  • 1. Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study.
    Evangelatos G; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
    Rheumatology (Oxford); 2022 Aug; 61(8):3408-3413. PubMed ID: 34850863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.
    Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
    Semin Arthritis Rheum; 2018 Jun; 47(6):883-889. PubMed ID: 29150207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.
    Evangelatos G; Tentolouris N; Sfikakis PP; Tektonidou MG
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38321577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques.
    Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
    Front Immunol; 2022; 13():1077166. PubMed ID: 36700208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.
    Torricelli AK; Ugolini-Lopes MR; Bonfá E; Andrade D
    Lupus; 2020 Mar; 29(3):256-262. PubMed ID: 31986962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
    Conti F; Spinelli FR; Alessandri C; Pacelli M; Ceccarelli F; Marocchi E; Montali A; Capozzi A; Buttari B; Profumo E; Sorice M; Arca M; Valesini G; Riganò R
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):661-8. PubMed ID: 24436371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.
    Vlachoyiannopoulos PG; Kanellopoulos PG; Ioannidis JP; Tektonidou MG; Mastorakou I; Moutsopoulos HM
    Rheumatology (Oxford); 2003 May; 42(5):645-51. PubMed ID: 12709540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.
    Panopoulos S; Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
    Lupus Sci Med; 2023 Mar; 10(1):. PubMed ID: 36868585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
    Frerix M; Stegbauer J; Kreuter A; Weiner SM
    Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.
    Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34921093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Jiménez S; García-Criado MA; Tàssies D; Reverter JC; Cervera R; Gilabert MR; Zambón D; Ros E; Bru C; Font J
    Rheumatology (Oxford); 2005 Jun; 44(6):756-61. PubMed ID: 15757967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.
    McMahon M; Skaggs BJ; Grossman JM; Sahakian L; Fitzgerald J; Wong WK; Lourenco EV; Ragavendra N; Charles-Schoeman C; Gorn A; Karpouzas GA; Taylor MB; Watson KE; Weisman MH; Wallace DJ; Hahn BH
    Arthritis Rheumatol; 2014 Jan; 66(1):130-9. PubMed ID: 24449580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome.
    Evangelatos G; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
    Rheumatology (Oxford); 2024 Apr; 63(4):1030-1038. PubMed ID: 37294733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.
    Papazoglou N; Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
    Rheumatology (Oxford); 2024 Jan; 63(1):50-57. PubMed ID: 37086440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
    Bundhun PK; Boodhoo KD; Long MY; Chen MH
    Medicine (Baltimore); 2016 Mar; 95(12):e3200. PubMed ID: 27015221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.
    Tektonidou MG; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Protogerou A
    Autoimmun Rev; 2017 Mar; 16(3):308-312. PubMed ID: 28147263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.
    Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
    Rheumatology (Oxford); 2018 Dec; 57(12):2158-2166. PubMed ID: 30102390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study.
    Panopoulos S; Thomas K; Georgiopoulos G; Boumpas D; Katsiari C; Bertsias G; Drosos AA; Boki K; Dimitroulas T; Garyfallos A; Papagoras C; Katsimbri P; Tziortziotis A; Adamichou C; Kaltsonoudis E; Argyriou E; Vosvotekas G; Sfikakis PP; Vassilopoulos D; Tektonidou MG
    Rheumatology (Oxford); 2021 Jan; 60(1):170-178. PubMed ID: 32596727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.
    Perez-Sanchez C; Barbarroja N; Messineo S; Ruiz-Limon P; Rodriguez-Ariza A; Jimenez-Gomez Y; Khamashta MA; Collantes-Estevez E; Cuadrado MJ; Aguirre MA; Lopez-Pedrera C
    Ann Rheum Dis; 2015 Jul; 74(7):1441-9. PubMed ID: 24618261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
    Sarzi-Puttini P; Atzeni F; Carrabba M
    Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.